sms
pharmaceuticals Limited
Registered & Corporate Office :
8th Floor, Trendset Jayabheri Connect,
Kondapur, Hyderabad - 500 084,
Telangana, India.
Tel : +91 - 40 - 6985 9999
CIN No. : L24239TG1987PLC008066
Email : info@smspharma.com, www.smspharma.com

Date: 01st August, 2026

To,

The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Dear Sir/Madam,

Sub: Press release on Financial Results

Please find enclosed the press release on the Financial Results for the quarter ended 30th June, 2026.

This press release may also be accessed on the website of the Company at www.smspharma.com

Kindly take the same on record and disseminate on your website.

Thanking you
Yours Faithfully

For SMS Pharmaceuticals Limited

THIRUMALESH TUMMA

Digitally signed by THIRUMALESH TUMMA
Date: 2026.08.01 16:12:15 +05'30'

Thirumalesh Tumma
Company Secretary

August 01, 2026

Consistent broad-based growth across high-value APIs

- Revenue up 6% YoY, driven by diversified growth across high-value APIs
- Gross margin remained above 45%, reflecting structural improvement in unit economics
- EBITDA margin sustained at ~20%; PAT up 8% YoY
- Completed 4 DMF/CEP filings; on track to meet FY27 target of 10 DMF/CEP filings
- ₹280 crore capex programme progressing as planned; expected to be completed by FY27
- Board approves infusion of up to ₹50 crore, as a loan, into subsidiary SMS Peptides Private Limited; building on the ₹8 crore investment made in FY26 to establish its dedicated peptide R&D facility
- R&D team strength increased to 200, supporting the development pipeline of niche and high-value APIs and peptides

SMS Pharmaceuticals Limited (SMS Pharma) (NSE: SMSPHARMA; BSE:532815), a diversified and integrated pharmaceutical company specialising in Active Pharmaceutical Ingredients (API) and complex Intermediates for global customers, has announced its unaudited financial results for the quarter ended June 30, 2026.

Commenting on the performance, Mr. P. Vamsi Krishna, Executive Director, stated*:*
"We have started FY27 on a healthy note with broad-based growth across our high-value API portfolio while maintaining EBITDA margins at around 20%. During the quarter, we continued to benefit from backward integration and an improving product mix, which supported consistently healthy gross margins and reinforced the structural improvement in our unit economics.

While our structural margin profile continues to improve, EBITDA margins during the quarter were impacted by annual employee increments, reflecting our continued investment in expanding our organisational capabilities and manpower in line with our short- and long-term growth strategy. Elevated freight costs arising from the geopolitical situation in West Asia also impacted EBITDA margins during the quarter. We expect these temporary headwinds to ease in the near future, providing further support to margin expansion alongside the continued benefits of backward integration and an improving product mix.

On the R&D front, we completed 4 DMF and CEP filings during the quarter, keeping us on track to achieve our FY27 target of 10 DMF/CEP filings. Our R&D team has developed a pipeline of 6 to 8 niche and high-value molecules, which are expected to enter commercial production towards the end of this financial year. In parallel, we are allocating additional capital of ₹50 crore to our peptide CDMO platform, in line with our strategy of building a differentiated portfolio of niche, high-value products.

Our ₹280 crore Capex programme is progressing as planned. Of the total outlay, ₹120 crore has been completed, with the remaining ₹160 crore expected to be completed by FY27. This will support the commercialisation of new niche and high-value molecules.

Looking ahead, we expect growth momentum to strengthen over the remaining quarters of FY27. Our ARV portfolio will continue to expand with the commercialisation of new molecules, while Ibuprofen is well positioned to deliver strong volume growth supported by improving realisations/margins. In addition, increasing contributions from high-value APIs and new product launches are expected to further support revenue growth. With a diversified portfolio, robust product pipeline and ongoing capacity expansion, we remain confident of delivering our FY27 growth guidance while sustaining EBITDA margins of 20%."

Summary of financial performance

(₹ Cr)

Particulars	Q1FY27	Q1FY26	YoY Growth (%)	Q4FY26	QoQ Growth (%)	FY26	FY25	YoY Growth (%)
Revenue from operations	207.0	196.1	6%	237.95	-13%	886.87	782.75	13%
Gross profit (Incl. manufacturing expenses)	74.9	66.7	12%	81.29	-8%	302.83	264.70	14%
Gross profit margin	36%	34%	217bps	34%	204bps	34%	34%	33bps
EBITDA	40.95	39.37	4%	39.90	3%	171	139	23%
EBITDA margin	20%	20%	-30bps	17%	302bps	19%	18%	155bps
PAT	20.20	18.72	8%	20.96	-4%	88	67	31%
PAT margin	10%	10%	21bps	9%	95bps	10%	9%	131bps
PAT after share of associate profit/loss	20.91	20.50	2%	32.71	-36%	102	69	47%
EPS	2.23	2.31	-3%	3.58	-38%	11.15	8.16	37%

Revenue by therapeutic area

(₹ Cr)

Particulars	Q1FY27		Q1FY26		YoY Growth (%)
	Revenue	As % of total revenue	Revenue	As % of total revenue	
Anti-diabetic	20.08	10%	65.16	33%	-69%
Anti Retro Viral (ARV)	65.22	32%	38.48	20%	69%
Anti-inflammatory	46.91	23%	45.25	23%	4%
Anti-migraine	24.79	12%	17.21	9%	44%
Anti-ulcer	10.11	5%	11.24	6%	-10%
Anti-erectile dysfunction	9.87	5%	2.73	1%	262%
Anti-epileptic	11.61	6%	7.70	4%	51%
Anti-anginal	11.88	6%	5.18	3%	129%
Others	6.49	3%	3.10	2%	109%

Performance review

Revenue from operations in Q1FY27 was ₹207.0 crore, up 6% YoY, driven by broad-based growth across high-value APIs. Strong growth in the ARV portfolio was supported by continued market share gains, while Ibuprofen continued to witness healthy demand from regulated markets. Growth was further supported by growing contribution from high-value APIs, reflecting the Company's continued focus on portfolio diversification.

Gross profit (Incl. manufacturing expenses) increased 12% YoY to ₹74.9 crore, with gross margin expanding 217 bps YoY to 36%, reflecting the benefits of backward integration and an improving product mix. EBITDA increased 4% YoY to ₹40.95 crore, while EBITDA margin remained healthy at 20%. PAT increased 8% YoY to ₹20.20 crore, with PAT margin remaining stable at 10%. The share of profit from our associate company, VKT Pharma Private Limited, stood at ₹0.71 crore during the quarter. Consequently, Net profit after tax and share of profit from associate was ₹20.91 crore.

Project update

Our ₹280 crore Capex programme is progressing as planned. Of the total outlay, ₹120 crore has been completed, with the remaining ₹160 crore expected to be completed by FY27. This will support the commercialisation of new niche and high-value molecules.

Outlook

We are on track to deliver our FY27 growth guidance with EBITDA margins of 20%. Growth will be supported by the completion of our capacity expansion programme, enabling the commercialisation of new niche and high-value molecules, alongside volume growth across our expanded ARV portfolio and anti-inflammatory products.

About SMS Pharmaceuticals Limited

Established in 1990, SMS Pharmaceuticals Limited is a diversified and integrated pharmaceutical company specialising in API and intermediates. The Company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 200 KL and 3,000 KL, respectively. Supported by strong in-house R&D capabilities, the Company has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to a global customer base in over 70 countries.

DISCLAIMER

This press release contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied. SMS Pharmaceuticals Limited undertakes no obligation to update these statements to reflect subsequent events or circumstances.

For any further information, please contact:

Company	Investor relations
SMS Pharmaceuticals Limited Mr. Thirumalesh Tumma Email: complianceofficer@smspharma.com	**Eqsponent Partners** Mr. Aditya Dutta Email: smspharma.IR@eqsponent.com